| Methods | Six-week randomised, double-blind, multicentre study. | |
| Participants | In- and outpatients fulfilling DSM-III-R criteria for predominantly major depressive disorder, with a score of at least 16 on the first 17 items of HDRS. Age range: over 18 years old. Exclusion criteria: not stated. |
|
| Interventions | Fluoxetine: 107 participants. Moclobemide: 102 participants. Fluoxetine dose range: 20-40 mg/day. Moclobemide dose range: 300-450 mg/day. Benzodiazepines were permitted only if strongly indicated. |
|
| Outcomes | Hamilton Rating Scale for Depression (HDRS-17), CGI, Montgomery and Asberg Scale for Depression | |
| Notes | Funding: by industry | |
| Risk of bias | ||
| Item | Authors’ judgement | Description |
| Allocation concealment? | Unclear | B - Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.